Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Selecta Biosciences Inc (NASDAQ: SELB) and Cartesian Therapeutics Inc announced a reverse merger in an all-stock deal, with Sel...
Concurrent with the merger, the combined company has been renamed Cartesian Therapeutics, Inc. The Company's Nasdaq ticker ...
Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develo...
Mizuho analyst Uy Ear maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $4 to $3.
SVB Leerink analyst Joseph Schwartz downgrades Selecta Biosciences (NASDAQ:SELB) from Outperform to Market Perform and annou...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Selecta Biosciences (NASDAQ:SELB) with a Buy and maintains $5 ...
Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $5 to $4.
